_id
691487ebccc777a4e85d9747
Ticker
OMMH
Name
Omnimmune Holdings Inc
Exchange
OTCCE
Address
4600 Post Oak Place, Houston, TX, United States, 77027
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
Description
Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization), and genomic-based products, which target a hormone called human chorionic gonadotropin. In addition, the company plans to conduct a Phase I trial with its lead candidate anti-human chorionic gonadotropin beta subunit monoclonal antibodies based upon the results of the diagnostic trial. Omnimmune Holdings, Inc. is based in Houston, Texas.
Last Close
0.0001
Volume
-
Current Price
0.0001
Change
0
Last Updated
2026-01-05T12:09:16.271Z
Image
data:image/webp;base64,UklGRkgBAABXRUJQVlA4IDwBAACwBwCdASpAAEAAPtFcpEuoJaOhsfjoAQAaCWkA0yyu0AAf1r+x8tz6XMI/5r/liywNL2aGlLK/3UW/aWmkeeoa3mQJLF8AAP7zC7+8A1o7j/Ies6tANoY9izXtGP2HON0t32GeyvfXpMDiUsHM+29uFYH/kuDlNFTkduEYcKI5GEVEXBaO336gVtGZDt7hljISf/MXzNNv76u7gAw7vp/cU1h6H/b3z0Zfvfx6z7CYoOd+vyeUyE0T55NqNv8Z1fRpdRb9VXpqEQd86lYspTPcQl7Oow0b8yUpgVSXh88AkmXj+JyAKn24wceRFFVteNjJZenbVcAA/oGBJ8P4fPVSMWiWeQVzUWFxNX8eWmrblAH18DZYns6S4yb5ML+XvNxwMPtmNshNaaq2/UsvcetkaiURvbXPwqmLCAAA
Ipo Date
-
Market Cap
980
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2010-09-30
Revenue
0
Cost Of Revenue
0
Gross Profit
0
Operating Expenses
224765
Operating Income
-224765
Interest Expense
78730
Pretax Income
-303495
Net Income
-303495
Eps
-
Dividends Per Share
-
Shares Outstanding
9807421
Income Tax Expense
0
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
-78730
Cash
4805
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
43530
Property Plant Equipment
-
Total Assets
43530
Payables
728948
Short Term Debt
987046
Long Term Debt
1050458
Total Liabilities
5762683
Equity
-5719153
Bs_currency_symbol
USD
Depreciation
19920
Change In Working Capital
-
Cash From Operations
-76609
Capital Expenditures
0
Cash From Investing
310000
Cash From Financing
-6370
Net Change In Cash
-82979
Cf_currency_symbol
USD
PE
-
PB
-
ROE
5.306642434640234
ROA
-697.2088215024121
FCF
-76609
Fcf Percent
-
Piotroski FScore
1
Health Score
38
Deep Value Investing Score
2.5
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
0.5
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
2
Quality Investing Score
1
Value Investing Score
1.5
Quarters > 0 > quarter
2010-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
0
Quarters > 0 > income Statement > gross Profit
0
Quarters > 0 > income Statement > operating Expenses
224765
Quarters > 0 > income Statement > operating Income
-224765
Quarters > 0 > income Statement > interest Expense
78730
Quarters > 0 > income Statement > pretax Income
-303495
Quarters > 0 > income Statement > net Income
-303495
Quarters > 0 > income Statement > eps
-
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
-
Quarters > 0 > income Statement > income Tax Expense
0
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-78730
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
4805
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
43530
Quarters > 0 > balance Sheet > property Plant Equipment
-
Quarters > 0 > balance Sheet > total Assets
43530
Quarters > 0 > balance Sheet > payables
728948
Quarters > 0 > balance Sheet > short Term Debt
987046
Quarters > 0 > balance Sheet > long Term Debt
1050458
Quarters > 0 > balance Sheet > total Liabilities
5762683
Quarters > 0 > balance Sheet > equity
-5719153
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-303495
Quarters > 0 > cash Flow > depreciation
19920
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-76609
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
310000
Quarters > 0 > cash Flow > cash From Financing
-6370
Quarters > 0 > cash Flow > net Change In Cash
-82979
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-
Quarters > 0 > ratios > PB
-
Quarters > 0 > ratios > ROE
5.306642434640234
Quarters > 0 > ratios > ROA
-697.2088215024121
Quarters > 0 > ratios > FCF
-76609
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
38
Quarters > 1 > quarter
2010-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
125000
Quarters > 1 > income Statement > gross Profit
-125000
Quarters > 1 > income Statement > operating Expenses
449607
Quarters > 1 > income Statement > operating Income
-449607
Quarters > 1 > income Statement > interest Expense
75073
Quarters > 1 > income Statement > pretax Income
-27608
Quarters > 1 > income Statement > net Income
-27608
Quarters > 1 > income Statement > eps
-
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
-
Quarters > 1 > income Statement > income Tax Expense
0
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
421999
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
87784
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
94458
Quarters > 1 > balance Sheet > property Plant Equipment
-
Quarters > 1 > balance Sheet > total Assets
94458
Quarters > 1 > balance Sheet > payables
694257
Quarters > 1 > balance Sheet > short Term Debt
987046
Quarters > 1 > balance Sheet > long Term Debt
1036003
Quarters > 1 > balance Sheet > total Liabilities
5521478
Quarters > 1 > balance Sheet > equity
-5427020
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-27608
Quarters > 1 > cash Flow > depreciation
11302
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-230077
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
310000
Quarters > 1 > cash Flow > cash From Financing
7271
Quarters > 1 > cash Flow > net Change In Cash
87194
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-
Quarters > 1 > ratios > PB
-
Quarters > 1 > ratios > ROE
0.5087138061035338
Quarters > 1 > ratios > ROA
-29.2278049503483
Quarters > 1 > ratios > FCF
-230077
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
33
Quarters > 2 > quarter
2010-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
0
Quarters > 2 > income Statement > gross Profit
0
Quarters > 2 > income Statement > operating Expenses
263611
Quarters > 2 > income Statement > operating Income
-263611
Quarters > 2 > income Statement > interest Expense
231934
Quarters > 2 > income Statement > pretax Income
-1001300
Quarters > 2 > income Statement > net Income
-1001300
Quarters > 2 > income Statement > eps
-
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
-
Quarters > 2 > income Statement > income Tax Expense
0
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-737689
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
590
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
16611
Quarters > 2 > balance Sheet > property Plant Equipment
-
Quarters > 2 > balance Sheet > total Assets
16611
Quarters > 2 > balance Sheet > payables
835231
Quarters > 2 > balance Sheet > short Term Debt
987046
Quarters > 2 > balance Sheet > long Term Debt
1025035
Quarters > 2 > balance Sheet > total Liabilities
5426422
Quarters > 2 > balance Sheet > equity
-5409811
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-1001300
Quarters > 2 > cash Flow > depreciation
178260
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
-188856
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
310000
Quarters > 2 > cash Flow > cash From Financing
183819
Quarters > 2 > cash Flow > net Change In Cash
-5037
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-
Quarters > 2 > ratios > PB
-
Quarters > 2 > ratios > ROE
18.508964546081184
Quarters > 2 > ratios > ROA
-6027.93329721269
Quarters > 2 > ratios > FCF
-188856
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
47
Quarters > 3 > quarter
2009-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
0
Quarters > 3 > income Statement > gross Profit
0
Quarters > 3 > income Statement > operating Expenses
398853
Quarters > 3 > income Statement > operating Income
-398853
Quarters > 3 > income Statement > interest Expense
62838
Quarters > 3 > income Statement > pretax Income
-461690
Quarters > 3 > income Statement > net Income
-461690
Quarters > 3 > income Statement > eps
-
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
-
Quarters > 3 > income Statement > income Tax Expense
0
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-62837
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
5627
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
31432
Quarters > 3 > balance Sheet > property Plant Equipment
-
Quarters > 3 > balance Sheet > total Assets
31432
Quarters > 3 > balance Sheet > payables
906893
Quarters > 3 > balance Sheet > short Term Debt
987046
Quarters > 3 > balance Sheet > long Term Debt
1032937
Quarters > 3 > balance Sheet > total Liabilities
5457287
Quarters > 3 > balance Sheet > equity
-5425855
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-461690
Quarters > 3 > cash Flow > depreciation
8072
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
-73924
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
310000
Quarters > 3 > cash Flow > cash From Financing
79551
Quarters > 3 > cash Flow > net Change In Cash
5627
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-
Quarters > 3 > ratios > PB
-
Quarters > 3 > ratios > ROE
8.509073685161141
Quarters > 3 > ratios > ROA
-1468.853397811148
Quarters > 3 > ratios > FCF
-73924
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
40
Annuals > 0 > quarter
2009-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
0
Annuals > 0 > income Statement > gross Profit
0
Annuals > 0 > income Statement > operating Expenses
1522060
Annuals > 0 > income Statement > operating Income
-1522060
Annuals > 0 > income Statement > interest Expense
0
Annuals > 0 > income Statement > pretax Income
-1761268
Annuals > 0 > income Statement > net Income
-1761268
Annuals > 0 > income Statement > eps
-
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
-
Annuals > 0 > income Statement > income Tax Expense
0
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-239208
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
5627
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
31432
Annuals > 0 > balance Sheet > property Plant Equipment
-
Annuals > 0 > balance Sheet > total Assets
31432
Annuals > 0 > balance Sheet > payables
906893
Annuals > 0 > balance Sheet > short Term Debt
987046
Annuals > 0 > balance Sheet > long Term Debt
1032937
Annuals > 0 > balance Sheet > total Liabilities
5457287
Annuals > 0 > balance Sheet > equity
-5425855
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-1761268
Annuals > 0 > cash Flow > depreciation
22317
Annuals > 0 > cash Flow > change In Working Capital
-
Annuals > 0 > cash Flow > cash From Operations
-252427
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
205439
Annuals > 0 > cash Flow > net Change In Cash
-46988
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-
Annuals > 0 > ratios > PB
-
Annuals > 0 > ratios > ROE
32.460653666564994
Annuals > 0 > ratios > ROA
-5603.423262916773
Annuals > 0 > ratios > FCF
-252427
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
41
Annuals > 1 > quarter
2008-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
0
Annuals > 1 > income Statement > gross Profit
0
Annuals > 1 > income Statement > operating Expenses
5475869
Annuals > 1 > income Statement > operating Income
-5475869
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-5989872
Annuals > 1 > income Statement > net Income
-5989872
Annuals > 1 > income Statement > eps
-
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
-
Annuals > 1 > income Statement > income Tax Expense
0
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-514003
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
52615
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
52615
Annuals > 1 > balance Sheet > property Plant Equipment
-
Annuals > 1 > balance Sheet > total Assets
52615
Annuals > 1 > balance Sheet > payables
471775
Annuals > 1 > balance Sheet > short Term Debt
287768
Annuals > 1 > balance Sheet > long Term Debt
1709899
Annuals > 1 > balance Sheet > total Liabilities
3796937
Annuals > 1 > balance Sheet > equity
-3744322
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-5989872
Annuals > 1 > cash Flow > depreciation
6794202
Annuals > 1 > cash Flow > change In Working Capital
-
Annuals > 1 > cash Flow > cash From Operations
-1910581
Annuals > 1 > cash Flow > capital Expenditures
0
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
1962987
Annuals > 1 > cash Flow > net Change In Cash
52406
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-
Annuals > 1 > ratios > PB
-
Annuals > 1 > ratios > ROE
159.97213914828907
Annuals > 1 > ratios > ROA
-11384.342868003421
Annuals > 1 > ratios > FCF
-1910581
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
40
Annuals > 2 > quarter
2008-05-31
Annuals > 2 > income Statement > revenue
445
Annuals > 2 > income Statement > cost Of Revenue
0
Annuals > 2 > income Statement > gross Profit
445
Annuals > 2 > income Statement > operating Expenses
0
Annuals > 2 > income Statement > operating Income
-47609
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
-47609
Annuals > 2 > income Statement > net Income
-47609
Annuals > 2 > income Statement > eps
-
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
-
Annuals > 2 > income Statement > income Tax Expense
0
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
-10698.651685393259
Annuals > 2 > income Statement > total Other Income Expense Net
6530829
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
3160
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
3160
Annuals > 2 > balance Sheet > property Plant Equipment
-
Annuals > 2 > balance Sheet > total Assets
3160
Annuals > 2 > balance Sheet > payables
8735
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
8735
Annuals > 2 > balance Sheet > equity
-5575
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-47609
Annuals > 2 > cash Flow > depreciation
6794202
Annuals > 2 > cash Flow > change In Working Capital
-
Annuals > 2 > cash Flow > cash From Operations
-70874
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
1962987
Annuals > 2 > cash Flow > net Change In Cash
-70874
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-
Annuals > 2 > ratios > PB
-
Annuals > 2 > ratios > ROE
853.9730941704036
Annuals > 2 > ratios > ROA
-1506.613924050633
Annuals > 2 > ratios > FCF
-70874
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-159.2674157303371
Annuals > 2 > health Score
41
Annuals > 3 > quarter
2007-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
0
Annuals > 3 > income Statement > gross Profit
0
Annuals > 3 > income Statement > operating Expenses
875794
Annuals > 3 > income Statement > operating Income
-875794
Annuals > 3 > income Statement > interest Expense
0
Annuals > 3 > income Statement > pretax Income
-2768669
Annuals > 3 > income Statement > net Income
-2768669
Annuals > 3 > income Statement > eps
-
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
-
Annuals > 3 > income Statement > income Tax Expense
0
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-1892875
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
209
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
10209
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
10209
Annuals > 3 > balance Sheet > payables
351482
Annuals > 3 > balance Sheet > short Term Debt
690799
Annuals > 3 > balance Sheet > long Term Debt
159506
Annuals > 3 > balance Sheet > total Liabilities
2764615
Annuals > 3 > balance Sheet > equity
-2754406
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-2768669
Annuals > 3 > cash Flow > depreciation
-
Annuals > 3 > cash Flow > change In Working Capital
-
Annuals > 3 > cash Flow > cash From Operations
-441719
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
412428
Annuals > 3 > cash Flow > net Change In Cash
-29291
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-
Annuals > 3 > ratios > PB
-
Annuals > 3 > ratios > ROE
100.51782489582146
Annuals > 3 > ratios > ROA
-27119.88441571163
Annuals > 3 > ratios > FCF
-441719
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
41
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
5.306642434640234
Profitability > metrics > ROA
-697.2088215024121
Profitability > final Score
26
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-2.8548837800076208
Risk > final Score
19
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.02536722156371176
Liquidity > metrics > Quick Ratio
0.02536722156371176
Liquidity > final Score
11
Liquidity > verdict
Weak
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
16
Prev Profitabilities > 1
52
Prev Profitabilities > 2
32
Prev Risks > 0
6
Prev Risks > 1
25
Prev Risks > 2
5
Prev Liquidities > 0
13
Prev Liquidities > 1
10
Prev Liquidities > 2
11
Updated At
2026-01-20T22:20:40.468Z
Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization), and genomic-based products, which target a hormone called human chorionic gonadotropin. In addition, the company plans to conduct a Phase I trial with its lead candidate anti-human chorionic gonadotropin beta subunit monoclonal antibodies based upon the results of the diagnostic trial. Omnimmune Holdings, Inc. is based in Houston, Texas.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2010-09-30)
Health Score
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 0.00% of the total shares of Omnimmune Holdings Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2010-09-30)
(Last Updated 2010-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2010-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2010-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.